In a similar context, small-molecule inhibitors of haspin, a different enzyme which phosphorylates H3, have been designed as antimitotic cancer therapies [249], and the oral administration of SEL120, a haspin inhibitor, led to promising results for the treatment of B-cell lymphomas [250]. The gene discussed is HASPIN; the disease is cancer.